Skip to main content Skip to main menu
UF Health University of Florida
Department of Anesthesiology College of Medicine
Submit an Abstract
Research Overview

Clinical Trials & Studies

Back Pain
Knee Pain
Diabetic Neuropathy
Anticoagulant Reversal

Lower Back and Sciatica Pain

SI Stem Cell Injection

Study Title

A phase 1, open label dose-ranging study to assess the safety, tolerability, preliminary efficacy, and dose effect of CFL001 cord blood product in patients with symptomatic sacroiliac joint syndrome.

Purpose

The overall objective is to evaluate the safety and potential efficacy effect of specific type of umbilical cord blood product (CFL001).

Basic Eligibility Criteria

  • 18 to 90 years old
  • SI joint syndrome
  • Have tried and failed other conservative pain therapies (i.e. Tylenol, NSAIDs, Tramadol, etc.)

Study Site Location(s)

Springhill 2 and Ayers

Contact

AROTeam@anest.ufl.edu

Anticoagulant Reversal

Takeda TAK330-3001

Study Title

A Phase 3, Prospective, Randomized, Open-label, Adaptive Group Sequential, Multicenter Trial with Blinded Endpoint Assessment to Evaluate the Efficacy and Safety of TAK-330 for the Reversal of Direct Oral Factor Xa Inhibitor-induced Anticoagulation in Patients Requiring Urgent Surgery/Invasive Procedure

Purpose

To compare the efficacy of TAK-330 to 4F-PCC used as a part of SOC for the reversal of direct oral Factor Xa inhibitor-induced anticoagulation in patients requiring urgent surgery/invasive procedure.

Basic Inclusion

  • 18 years of age and older
  • has taken an Anti-Xa medication (Eliquis (Apixaban), Xarelto (Rivaroxaban) or Savaysa (Edoxaban)) in the last 15 hours, or at any time beyond that if plasma anti-Fxa levels are elevated
  • in need of urgent/emergent surgery (excluding cardiac catheterization, endoscopy, minor procedures)Study site location:

Study Site Locations

STH & HVN

Contact

Anesthesiology Research Operations team, AROTeam@anest.ufl.edu

Octapharma

Study Title

Study of four-factor prothrombin complex concentrate, OCTAPLEX, in patients with acute major bleeding on direct oral anticoagulant (DOAC) therapy with factor Xa inhibitor

Purpose

To show effectiveness of OCTAPLEX for emergency reversal of the anticoagulant effect of DOACs in patients with major bleeding associated with factor Xa inhibition

Basic Inclusion Criteria

  • 18 years of age and older
  • Patients who received or who are believed by the investigator to have received a dose of oral factor Xa inhibitor (Eliquis (Apixaban), Xarelto (Rivaroxaban) or Savaysa (Edoxaban))
  • Patients who have acute major bleeding

Study Site Location

STH & HVN

Contact

Anesthesiology Research Operations team, AROTeam@anest.ufl.edu